US EditionPublished • loading... • Updated
Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial
Psyence BioMed has received formal approval from the Bellberry Human Research Ethics Committee (HREC), Australia, to use psychedelic active pharmaceutical ingredient (API) developer, PsyLabs’ psilocybin product (NPX5) in its ongoing Phase IIb study.The post Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
